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Researchers and clinicians are interested in how a patient’s individual genetic 
makeup could predict the appropriate medication and dose for that patient. One 
way to predict drug response, or efficacy, is by looking at enzymes within the 
liver that metabolize drugs. Many of these enzymes belong to a class called the 
Cytochrome P450s (CYPs). Specifically, two closely related enzymes, CYP3A4 
and CYP3A5, are involved in metabolizing 50% of drugs currently on the market 
(eg: statins, antiepileptics, anticancer agents, and antidepressants). There can 
be differences in the genetic code of these enzymes that can causes changes in 
drug metabolism.  
  
We completed a study with participants from the Confederated Salish and 
Kootenai Tribes (CSKT), located on the Flathead Reservation in northwest 
Montana. Select CYP enzymes were genotyped, including CYP3A4 and CYP3A5. 
Most SNPs identified in the CSKT participants were found at frequencies similar 
to those reported in European-descended populations. Interestingly, one specific 
SNP, called CYP3A4*1G, was discovered at a high allele frequency. The 
physiological significance of this SNP is unclear as there are limited and 
confounding data, however, most of the data published to date suggest that the 
SNP causes decreased metabolism of drugs. Clinically, this could result in a 
need for a decreased dose of medication. In addition, this CYP3A4 SNP was 
observed to be often inherited with another SNP in the related CYP3A5 gene, 
called CYP3A5*3, which encodes a nonfunctional enzyme. These SNPs found in 
the CSKT are of particular interest, because inheriting these two SNPs together 
could cause drastic changes in drug metabolism since the two enzymes 
metabolize many of the same drugs.  
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Chapter 1: Introduction  
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1.A. The Promise of Pharmacogenomics 
Pharmacogenomics offers a new way of practicing medicine by individualizing 
medications and dosages based on an individual’s genetic make-up [1, 2]. The 
goal is to optimize efficacy while minimizing adverse events [3]. The completion 
of the Human Genome Project in 2000 allowed scientists to more easily link 
specific genetic changes to differences in drug response and toxicity [1, 2].  
 
The Federal Drug Administration (FDA) states that its “mission is to protect and 
promote the health of all Americans through assuring the safety, efficacy, and 
security of drugs…” [4]. The FDA believes personalized medicine has potential to 
increase efficacy and decrease risk of adverse drug reactions [4]. They have 
released guidelines to better integrate genetic information with medications [4-6] 
[3]. These are guidelines for new drug applications as well as when, how, and 
what pharmacogenomic data to submit [3]. They have also required that 
pharmacogenomic data be included in the product insert of 140 different 
medications, many with more than one predictive biomarker; the importance of 
these biomarkers can vary from drug choice, to dosage, to black box warnings [4]. 
Medications with pharmacogenomic data in the product insert are widespread: 
trastuzumab (oncology), tamoxifen (oncology), phenytoin (neurology), warfarin 
(hematology/cardiology), clopidogrel (cardiology), abacavir (infectious diseases), 
atorvastatin (endocrinology), codeine (anesthesiology), and fluoxetine 
(psychiatry). This information is available to the public on their website under the 
Table of Pharmacogenomic Biomarkers in Drug Labeling [7]. Also in 2007, the 
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FDA approved the first genotyping test, a DNA microarray, Amplichip CYP450. 
This is used by physicians to assist in medication and dosage choices [8].  
 
Another organization that releases pharmacogenetics-guided dosing 
recommendations is the Clinical Pharmacogenetics Implementation Consortium 
(CPIC). The CPIC was formed in 2009 and focuses on providing guidelines 
designed to help providers understand how genetic test results should be used to 
optimize drug therapy in clinical practice [9]. To date, they have identified 174 
gene-drug pairs of interest, which include 63 unique genes and 131 unique drugs. 
CPIC has published guidelines on 33 of these pairs. These 174 gene-drug pairs 
are broken down into levels (A, B, C, or D) that indicate level of evidence and 
strength of recommendation. Level A indicates there is evidence to change 
prescribing regimen of drug, while Level D indicates there is weak or conflicting 
evidence and no changes in the prescribing regimen are recommended at this 
time. Codeine, phenytoin, simvastatin, and warfarin are considered Level A. 
Fluoxetine, tamoxifen, and omeprazole are considered Level B. Level C drugs 
include propranolol and diazepam, and Level D drugs include aspirin, 
atorvastatin, caffeine, and metformin [10]. 
 
One CPIC Level A drug is tacrolimus, a medication given to patients who 
undergo solid organ or hematopoietic cell transplantation to prevent rejection. 
Tacrolimus has a very narrow therapeutic window and plasma levels are strictly 
monitored by therapeutic drug monitoring; too little drug leads to organ or graft 
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rejection while too much drug leads to nephrotoxicity [11-13]. In spite of individual 
monitoring, patients still experience lack of efficacy or adverse events. The 
clearance of tacrolimus is mediated by drug-metabolizing enzymes, cytochrome 
P450 3A4 (CYP3A4) and 3A5 (CYP3A5), which determine drug levels in the 
body. In vitro and in vivo data show that individuals with genotypes encoding for 
deleterious CYP3A5 enzyme function have lower clearances and higher trough 
concentrations than those expressing wildtype enzyme [14-18]. Using CYP3A4 
and CYP3A5 genotypes to more accurately determine tacrolimus dosage 
regimens can improve efficacy through less dosage modifications and quicker 
time to target tacrolimus plasma concentrations [19].  
 
1.A.i. Pharmacogenetics: Improving Outcomes 
Most medications used today are efficacious in only 25% (oncology medications) 
to 80% (analgesic medications) of patients [4, 20]. Although efficacy can be 
affected by several factors such as patient compliance, diet, and drug 
interactions, genetic variations can play a large role [3]. Identifying patients at risk 
for adverse events can help to minimize injuries as well as reduce medical costs. 
Adverse drug reactions (ADRs) refer to significant side effect(s) of medications, 
some of which can be life threatening [21-23]. The Institute of Medicine reports 
that there are at least 1.5 million preventable ADRs in the United States (US) per 
year and they are considered the leading cause of preventable death [24, 25]. As 
a result of ADRs, there are more than 100,000 deaths per year in the US costing 
$100 billion per year [26]. Pharmacogenomics may be able to play a role in 
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reducing these adverse events by predicting those at higher risk due to a change 
in drug metabolism. 
 
Interindividual variability in drug response and toxicity is multifactorial and include 
both extrinsic and intrinsic factors. Extrinsic factors include the environment (i.e. 
smoking, diet, and alcohol consumption) and drug interactions (i.e. concomitant 
use of other prescription medications, over-the-counter medications, and herbal 
supplements). Intrinsic factors include demographics (age, gender, and ethnicity) 
and disease (particularly liver and kidney dysfunction). Finally, genetic variation 
between individuals can also be a key player in differences in response and 
toxicity [27-30]. It has been proposed that genetic factors can account for as 
much as 20-95% of interindividual variability in drug disposition [31]. This wide 
estimation accounts for different effects of genetic factors in different gene-drug 
pairs. The amount of interindividual variability can be drug specific; it will affect 
metabolism rates differently depending on the drug given. Also, drug elimination 
pathways can be very complex, causing genetic factors to have different effects.  
 
1.A.ii. Genotype-Phenotype Associations 
Genotype-phenotype association studies are important in order to make a 
prediction about how a patient’s genetic variation, or their genotype, can affect 
the response or toxicity to a given medication, known as their phenotype. Genetic 
variation can affect the outcome of about a quarter of all medications [29]. It is 
	   6	  
important to identify individuals carrying these variations so that alternative 
medications or doses may be chosen. 
 
Most genotype-phenotype correlations can be measured through in vivo or in 
vitro probe drug assays [32]. Probe drugs are metabolized by a single drug-
metabolizing enzyme and are administered to identify the function of that enzyme. 
Phenotypes can be measured through administration of a subtherapeutic dose of 
probe drug [33]. When using probe drugs to measure a phenotype, plasma and 
urine concentrations of the parent drug and metabolite are measured in order to 
estimate the pharmacokinetics of the parent and metabolite(s) [33, 34]. An 
advantage of this method is that phenotype is directly measured under current 
conditions (diet, age, disease state, etc). However, there are several 
disadvantages. This method can have complicated protocols and there is a risk 
of determining the wrong phenotype to do concurrent medications or disease 
state. There is also a risk of an ADR in patients of extreme phenotypes [34]. 
However, in clinical practice, phenotype is typically measured by a clinical 
outcome (i.e. INR for warfarin or reducing LDL levels for statins) [35]. 
 
There are four phenotypes: Poor Metabolizers (PM), Intermediate Metabolizers 
(IM), Extensive Metabolizers (EM), and Ultra Metabolizers (UM). PMs do not 
express active enzyme. This can cause increase risk of toxicity if the medication 
is toxic but decreased efficacy if metabolite is active. IMs have reduced enzyme 
activity. These patients continue to have lower metabolism than the standard 
	   7	  
population. EMs express fully active enzyme and standard doses are given to 
these patients. UMs have multiple copies of functional enzyme. These patients 
may have increased risk for toxicity if the metabolite is toxic or decreased 
efficacy if the parent medication is active [8, 33, 34, 36].  
 
Genotyping allows practitioners to optimize the drug choice and dose for each 
individual and avoid most ADRs. These can lead to decreased medical costs [34]. 
Genotyping can have the largest clinical impact on patients taking narrow 
therapeutic medications, patients with unexplained side effects, as well as, older 
patients. Older patients tend to take more medications and are more likely to 
exhibit serious side effects; they also can display large changes in metabolism 
due to decreased liver and kidney function [37].  
 
1.A.iii. Sources of Genetic Variability in Drug Response and Toxicity 
Pharmacogenetic variability results from genetic variation in both 
pharmacokinetic and pharmacodynamic properties of a drug. Pharmacokinetics 
is the study of the effect of the body on drugs, while pharmacodynamics is the 
study of the effects of drugs on the body. Alterations in pharmacokinetic 
pathways alter the drug exposure in an individual and make up the vast majority 
of pharmacogenetic variability.  
 
The pharmacokinetic disposition of a xenobiotic can be broken down by the 
processes of absorption, distribution, metabolism, and elimination (ADME) [38]. 
	   8	  
Absorption describes the processes that control the rate and extent of absorption 
of a compound from the site of administration to the systemic circulation. These 
processes include passive diffusion (small, lipophilic xenobiotics), active or 
facilitated transport (large, polar, or charged xenobiotics), and first-pass 
extraction in the gastrointestinal tract and liver for drugs that are orally 
administered [39]. After xenobiotics have entered systemic circulation, they are 
distributed from the vasculature to various tissues of the body, including those 
where they exert pharmacologic, and perhaps toxic, effect. The extent of this 
distribution depends upon passive and active diffusion rates across membranes 
and protein binding in both blood and tissues [38]. Metabolism mainly occurs in 
the liver, however, other tissues are known to have some metabolism such as 
kidney, lungs, and intestines [40]. Substrates undergo a wide range of metabolic 
reactions. Most undergo Phase I metabolism where the substrate undergoes 
oxidation, reduction, or hydrolysis reactions. Next, drugs often undergo 
sequential Phase II metabolism, which are conjugative reactions [38]. Hepatic 
metabolism is a primary component in the clearance of many compounds. 
Metabolism also plays a large role in first-pass extraction in the intestine and liver 
and, consequently, has a large effect on bioavailability of compounds that are 
extensively metabolized [38, 41]. Elimination of xenobiotics includes both the 
processes of metabolism and excretion. The primary routes of excretion are 
biliary excretion, via transporters, in the liver [42] and urinary excretion in the 
kidneys, by glomerular filtration and passive and active secretion via transporters 
[38, 43]. 
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Phase I enzymes are made up of mostly heme thiolate proteins called 
cytochrome P450s (CYPs) that facilitate hydroxylation, reduction, and oxidation 
reactions to convert lipophilic compounds to more hydrophilic compounds that 
are more easily excreted [34, 37, 44, 45]. These enzymes metabolize a wide 
variety of medications, steroids, fatty acids, and procarcinogens [46]. Examples 
of CYPs are CYP1A2, CY2C9, CYP2C19, CYP2D6, and CYP3A4 [38]. Phase II 
enzymes are conjugative by taking advantage of the hydrophilic groups added by 
Phase I enzymes. These conjugative reactions are mainly glucuronidation, 
sulfation, acetylation, and methylation. Examples of these enzymes are UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione S-
transferases (GSTs) [34, 37, 38]. Drug transporters are important in transporting 
hydrophilic drugs, metabolites, and conjugated metabolites across cell 
membranes and facilitating their elimination in the bile and urine. Drug 
transporters are also important in mediating delivery of drugs or their metabolites 
to their therapeutic target. Important examples of drug transporters are P-
glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), organic 
anion transporters (OATs), organic cation transporters (OCTs), and organic 
anion transporting polypeptides (OATPs) [34, 47, 48].  
 
Genetic variation in drug-metabolizing enzymes and drug transporters are of key 
importance in pharmacogenomics. A variety of genetic modifications can cause 
alterations to these proteins, including gene deletions and duplications, known as 
copy number variation (CNV), insertions and deletions, as well as point mutations, 
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known as single nucleotide polymorphisms (SNPs). A polymorphism is defined 
as a genetic mutation that is present at a frequency of greater than 1% [34]. 
Genetic variation can occur in coding (exons) or noncoding (introns, 5’UTR and 
3’UTR) regions [3]. 
 
1.B. Cytochrome P450s  
The cytochrome P450 family is the most important class of enzymes in overall 
drug metabolism, accounting for 78% of metabolism of drugs cleared through the 
liver [49]. The Human Genome Project has identified 57 active enzymes and 58 
pseudogenes [37, 50-52]. CYPs are a superfamily of hemeproteins, which are 
found in the smooth endoplasmic reticulum (ER) membrane. These enzymes 
have two main roles: metabolize exogenous drugs and xenobiotics as well as 
metabolize hormones, vitamins, and fatty acids [53]. They are expressed in 
several extrahepatic tissues including the intestine, lung, kidney, and brain but 
are preferentially expressed in the centrilobular area of the liver [34, 37, 54]. 
“Cyto” refers to microsomal vesicles while “chrome” refers to color. The “P” 
alludes to the pigmentation, red, conferred by the heme, and 450 refers to the 
maximum absorbance of 450 nm when the enzyme is bound to carbon monoxide 
[8, 36, 37, 55, 56].   
 
There are 16 human families of CYPs [33, 34, 36, 55]. A family is defined as 
enzymes that have ≥40% amino acid identity and are designated by a number. 
Families are divided into subfamilies that have ≥ 55% amino acid identity and are 
designated by a number. Finally, numbers are given to designate different genes 
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[36, 37, 55, 57]. There are 3 major groups of CYPs: 1) CYP1-3 families have 
lower affinity for substrates and are less conserved but are responsible for 70-
80% of all Phase I metabolism 2) CYP4 family metabolizes fatty acids and some 
xenobiotics and 3) CYP5-51 families have high affinity for endogenous 
substrates and are relatively well conserved [34, 37]. 
 
1.B.i. CYP Evolution 
The first cytochrome is believed to have arisen less than 3.5 billion years ago 
and to have functioned anaerobically [58, 59]. Since then, CYPs have undergone 
multiple rounds of expansion facilitated by gene duplication. The first round 
occurred around 1.5 billion years ago. This expansion gave rise to CYPs that 
metabolized fatty acids and cholesterol [60]. The next expansion occurred 
around 900 million years ago. This resulted in CYPs that metabolize steroids. 
One of these CYPs later gave rise to current day CYP families 1 and 2. Finally, 
400 million years ago, CYPs underwent another round of expansion. This 
resulted in several CYP families that metabolize xenobiotics. This last expansion 
is thought to be driven by aquatic organisms vast change in diet upon 
introduction onto land as well as terrestrial organisms introduction to combustion 
products [61, 62].  
 
Despite multiple distinct rounds of expansion, most CYP families are 
continuously changing. Gene duplication allows for one copy to diverge while the 
other copy maintains its original function. This often creates a pseudogene, 
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however it sometimes increases the overall fitness of the organism. For example, 
CYP often arose by metabolizing toxic substances from organisms’ diets [62]. 
Because CYPs are beneficial in order to process a wide variety of changing 
toxins, they have become a rapidly evolving gene. Change in a gene is 
measured by length of time for a unit of evolutionary period. CYPs unit of 
evolutionary period is about 2 – 4 million years. However, histones unit of 
evolutionary period is about 400 million years while immunoglobulins are about 
700,000 years [61, 62].  
  
1.B.ii. CYP Structure and Conserved Regions 
Most CYPs have around 480 to 560 amino acids. They can be categorized into 
three groups based on location: 1) ER membrane (microsomal-type) 2) 
mitochondrial membrane (mitochondrial-type) or 3) cytosol (rare in eukaryotes) 
[57]. Microsomal CYPs are differentiated by their signal-anchor sequence, 
located at the N-terminal, which targets the enzyme to the endoplasmic reticulum 
membrane. This signal domain is made up of 20-25 hydrophobic residues and is 
distinguished by charged residues on either side, basic residues toward the C-
terminal and negative residues near the N-terminal. These charged residues 
ensure that the CYP is properly inserted into the membrane, luminal side of the 
ER with enzyme exposed to cytoplasm. The hydrophobic region serves as the 
stop-transfer sequence [57, 63-65]. However, mitochondrial CYPs have a 
mitochondria-targeted sequence instead. This sequence acts to stall the folding 
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of the catalytic site until enzyme is transported into the mitochondria where it is 
then cleaved [57]. 
 
Although the CYP superfamily share only 20% sequence identity, they do share 
overall folding and topology [66]. They have an alpha helix rich carboxy-terminal 
and a beta-sheet rich amino-terminal [46]. Parallel helices (D, L, and I) as well as 
antiparallel helix (E) make up the common structure [67]. The heme binds 
between helix I and L to the Cys-heme-ligand loop containing the sequence, 
FxxGx(H/R)xCxG; the cysteine is essential as if forms the fifth ligand to the heme 
[68, 69]. Helix I is located near the center of the enzyme and within the heme 
pocket. It contains the conserved sequence (G/A)Gx(D/E)T. The threonine 
residue is part of the oxygen-binding pocket and is involved in catalysis [70-72]. 
Another conserved sequence, EXXR, is located in helix K. This sequence is key 
for enzyme function [69]. 
 
There are six substrate recognition sites located within helices F, G, and I [73]. 
These sites affect substrate specificity and are flexible to accommodate better 
substrate binding [74]. Any genetic changes that alter amino acid residues within 
regions can cause changes in drug affinities and metabolism [73]. 
 
1.B.iii. CYP Biochemistry and Catalytic Cycle 
CYPs oxidize various toxins, medications, and endogenous substrates. 
Mechanistically, these enzymes split molecular oxygen to incorporate one as a 
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functional group on the substrate while the other is released as a water molecule. 
This reaction requires an electron donor, the reducing agent NADPH. The 
general formula is NADPH + O2 + SH + H+ -> NAD(P)+ + SOH + H2O [46]. Figure 
1.1 illustrates the general CYP catalytic cycle. CYPs remain in an unreactive 
state until binding of the substrate. The first step is a transfer of an electron from 
cytochrome P450 reductase to reduce the iron from 3+ to 2+ charge. Next, the 
CYP complex binds molecular oxygen and triggers another electron transfer from 
either cytochrome P450 reductase or cytochrome b5. Two protons are accepted 
and the iron returns to a 3+ state. Finally, an oxygen atom is transferred to the 
substrate. The oxidized substrate is then released [75, 76]. There are three 
abortive steps (Figure 1.1), called uncoupling, within this cycle that return the 
enzyme to its resting state. Each produce either a superoxide anion, hydrogen 
peroxide, or water and occur at different intermediate states [77]. 
 
1.B.iv. CYP Regulation 
There are four different types of CYP regulation: xenobiotic-inducible [78], sex-
specific, tissue-specific [79], and developmental [80] regulation. CYP induction 
is an important mechanism in protecting an organism from changing toxins. For 
example, phenobarbital is a known broad CYP inducer [78, 81]. There are three 
receptors present in the cytosol that detect toxins. The pregnane X-receptor 
(PXR) regulates CYP2C9 and CYP3A4 [82-85], the aryl hydrocarbon receptor 
(AhR) regulates CYP1A1 and CYP1A2 [86], while constitutive androgen 
receptor (CAR) regulates CYP2C9 and CYP3A4 [82-85]. There have been 
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polymorphisms reported in all three of these receptors that effect CYP 
expression [87]. CYPs are also regulated in a sex-specific manner through the 
endocrine system and gonadal hormones. The endocrine system also plays a 
role in tissue-specific regulation [88]. 
 
1.C. Academic-Community Research Partnership with the Confederated 
Salish and Kootenai Tribes 
The Confederated Salish and Kootenai Tribes (CSKT) are located in northwest 
Montana on the Flathead Indian Reservation. Three tribes reside on this 
reservation as part of CSKT: the Bitterroot Salish, Upper Pend d’Oreille, and 
Kootenai. Our laboratory is involved in a research partnership with CSKT to 
explore the use of pharmacogenomics within the tribe. With personalized 
medicine on the rise, some populations with health disparities are not always 
included in research, and therefore, do not benefit from gene-guided therapies. 
There is little known about pharmacogenomic variation within understudied 
populations, like American Indian populations. Because allele frequencies are 
diverse among world populations, allele frequencies within American Indians 
cannot be assumed to be similar to other studied populations [89, 90]. It is 
important to investigate frequencies of genetic variants in all populations in order 
to utilize pharmacogenomic testing. 
 
Members of our laboratory have met with Tribal Council, Tribal Health, and a 
community advisory board to assure there is proper approval before any 
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research began. The community stated their main interest was in anticancer 
pharmacogenomics, mainly tamoxifen. CYP2C9, CYP2D6, CYP3A4, and 
CYP3A5 are responsible for 75% of all phase I drug metabolism, including 
several other anticancer agents. Therefore, our laboratory analyzed blood 
samples from tribal volunteers to explore the genetic variation with CYP2C9, 
CYP2D6, CYP3A4, and CYP3A5. Research participants, 18 years and older, 
were recruited at powwows, health fairs and career fairs and were asked tribal 
affiliation and blood quanta. DNA was extracted from whole blood and CYP2D6 
(entire gene) was resequenced in 187 participants, while CYP2C9, CYP3A4, and 
CYP3A5 (exons and flanking intron regions) was resequenced in 94 random 
participants [90]. 
 
1.C.i. CYP2C9 Resequencing 
CYPC9 makes up 20% of hepatic CYP content and metabolizes about 15% of 
medications currently on the market, several with narrow therapeutic windows. 
Table 1.1 lists common substrates, inducers, and inhibitors for CYP2C9. 
Examples of substrates are warfarin, ibuprofen, and phenytoin [3, 36, 37, 46]. 
There are two important variants of CYP2C9, CYP2C9*2 and CYP2C9*3 (Table 
1.2) that can cause large interindividual variability as well as cause adverse 
events [91, 92]. Together, these alleles are in seen in about 18% of European 
descendants, but much less so in other populations (Table 1.3). CYP2C9*2 and 
CYP2C9*3 encode for proteins with reduced intrinsic clearance. This effect is 
substrate specific but can caused reduced activity up to 90% [92, 93]. 
	   17	  
 
In resequencing CYP2C9 in the CSKT population, our laboratory found 41 SNPs, 
11 novel (most with very low frequencies). Also CYP2C9*2 and CYP2C9*3 were 
found to at a frequency lower than those found in European descendants. These 
SNPs cause decrease function but, due to their low frequencies, may play a 
minor role in CYP2C9 interindividual variability in the CSKT. Also, low level of 
linkage was seen between CYP2C9 SNPs. Table 1.3 lists the allele frequencies 
of interesting SNPs identified in the CSKT population.  
 
1.C.ii. CYP2D6 Resequencing 
CYP2D6 is another important drug-metabolizing enzyme in the CYP2 family. 
There are several polymorphisms of CYP2D6 that can cause a large clinical 
impact (Table 1.4). Although it only makes up two percent of total hepatic CYP 
content, it takes part in the metabolism of 15% of drugs on the market. CYP2D6 
metabolizes several different substrates: propranolol, paroxetine, trazodone, 
codeine, and fentanyl (Table 1.1) [46, 49]. CYP2D6 is the only non-inducible 
CYP, so genetic variation accounts for much of the interindividual variability [49, 
94]. There are more than 80 known variants, which could drastically change 
metabolism [95]. PMs are more common in Caucasians with 5-10% expressing a 
null allele. However, only 0-1% of Africans and Asians are classified as PMs. The 
most common allele responsible for the PM phenotype is CYP2D6*4. IMs are 
more common in Asians with 50% expressing the CYP2D6*10 allele. Only, 10-
15% of Caucasians are classified as IMs, expressing the CYP2D6*41 allele, 
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encoding for a SNP that causes a fraction to missplice, and 30% of Africans 
express the CYP2D6*17 allele. UMs are more common in African populations. 
The frequency of gene duplications is present in up to 50% in some populations 
and can cause up to 30-fold higher amounts of metabolite [94, 96]. It is thought 
that gene duplications evolved as a result of dietary pressure [94]. 
 
Upon resequencing CYP2D6 in the CSKT population, our lab found 76 SNPs 
with 9 identified as novel. Individuals with multiple copies of CYP2D6 were found 
to be low in this population (1.34% of alleles). The major SNPs were found to be 
at similar frequencies found in Caucasians (Table 1.5); 1.1% are UM, 87.2% are 
EM, 3.2% are IM, and 5.9% are PM. However, there was a high level of linkage 
seen between CYP2D6 SNPs, including several novel haplotypes identified. The 
functional consequences of these haplotypes are unclear. 
 
1.C.iii. CYP3A4 and CYP3A5 Resequencing 
CYP3A4 is the highest expressed CYP in the liver and intestine, making up to 
60% of total hepatic CYP expression [97]. Also, its presence in the small intestine 
is a large factor of first-pass effect [98]. CYP3A4 metabolizes a large range of 
substrates, totaling more than 120 different medications (Table 1.1), such as 
midazolam, saquinavir, erythromycin, diazepam, verapamil, tacrolimus, and 
simvastatin. CYP3A4 also metabolizes procarcinogens and endogenous 
substrates like testosterone and progesterone [99].  
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Most variants within CYP3A4 occur at a frequency of less than 5% and rarely 
occur has homozygotes, [30, 32, 100-105] although, not all have been well 
characterized. Figure 2.2 shows a map of the exons and introns of CYP3A4 with 
relative locations of major SNPs.  
 
CYP3A4*1B has been identified in the 5’UTR, however, there is confounding 
data as to its clinical effect. Some investigators report this SNP causes 
decreased nuclear protein binding [106] and its presence has been linked to 
different diseases such as prostate cancer [107, 108]. However, in vivo and in 
vitro data using probe drugs are not so clear. Using a luciferase expression 
assay, investigators report an increased rate of expression for the CYP3A4*1B 
allele [109, 110]. Although not significant, it has also been reported that human 
livers expressing this SNP have an increased rate of nifedipine metabolism. 
However, other in vitro and in vivo studies show no such association between 
genotype and phenotype [101, 111, 112]. 
 
Coding SNPs seem to be more localized within exons 5-7 and 11-12 and 
frequencies are reported to be low (<5%). Most SNPs result in minimal, if any, 
change in drug metabolism. Those that do change enzyme activity, appear to do 
so in a substrate dependent fashion. CYP3A4*2 causes decreased clearance 
and a 6-fold increase in the Km in nifedipine metabolism, however, no change in 
the metabolism rate of testosterone [102, 113]. CYP3A4*3 encodes for a SNP 
within the heme-binding pocket, although, no change in clearance is observed 
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[103, 104, 114]. CYP3A4*8 and CYP3A4*13 are reported to have low protein 
content in a cells and are expected to cause decreased levels in vivo [103, 104]. 
CYP3A4*12 results in an increased clearance of testosterone 15β and 2β-
hydroxylation [103]. CYP3A4*17 is reported to cause a reduction in testosterone 
metabolism while CYP3A4*18 causes an increase in testosterone metabolism 
[104].  
 
Intronic SNPs are more rare and are mostly present at a frequency of less than 
1%, however, a few are reported at much higher frequencies. G20338A and 
T15871C are present at approximately 50% in African American and 6.5% in 
Caucasians. Interestingly, these two alleles are commonly inherited together in 
African Americans, although no clinical significance has been reported [100]. 
CYP3A4*1G is another SNP, located in intron 10, seen at higher frequencies in 
various populations [115]. There is mixed data, although, most suggest 
decreased clearance [116-120]. CYP3A4*22, located in intron 6, is found in 
Caucasian populations [121, 122]. Again, this SNP has mixed data, however, 
most suggest it leads to decreased clearance [122-126]. 
 
Resequencing CYP3A4 in CSKT populations resulted in identification of 15 SNPs, 
of which 4 are novel SNPs. Major SNPs identified are listed in Table 1.6. All 
SNPs were seen with frequencies similar to Caucasians, except for CYP3A4*1G, 
seen with a frequency similar to Japanese and Chinese populations (26.8%) 
(Table 1.7). This results in 7% of individuals with the homozygous, 
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CYP3A4*1G/*1G genotype, and 39% as heterozygous for *1G. This SNP has 
conflicting data as to its clinical relevance and will be discussed in section 1.C.v. 
  
CYP3A5 is expressed in the liver, and is the only CYP3A isoform expressed 
outside the liver and intestine tissues, such as the kidney [127], prostate [128], 
and lung [129, 130]. CYP3A5 has a similar structure to CYP3A4 and metabolizes 
many of the same substrates, however, it usually does so with slower turnover 
rates [131, 132]. Because CYP3A4 and CYP3A5 have similar substrates, there is 
no known specific substrate of CYP3A5. This makes it difficult to measure 
CYP3A5 specific activity [129]. 
 
Polymorphisms with the largest clinical impact can be divided into coding region 
variants and intronic SNPs that cause frameshifts or splicing defects [129]. 
Figure 2.2 shows a map of introns and exons and the location of the major SNPs. 
SNPs have been reported within the 5’ untranslated region, CYP3A5*1B and 
CYP3A5*1C, however, they are seen to have no clinical significance [100, 133]. 
CYP3A5*6, *7, *8, *9, and *10 are all SNPs within the coding region that result in 
change in enzyme function. CYP3A5*6 results in a truncated, nonfunctional 
protein [100, 129]. CYP3A5*7 actually encodes for a base insertion that causes a 
frameshift, and again, a nonfunctional protein [129, 133, 134]. CYP3A5*8 and 
CYP3A5*9 encode for amino acid changes that result in roughly 50% enzyme 
activity. CYP3A5*10 results in an inactive enzyme through an amino acid change 
in the heme-binding region [129].  
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CYP3A5*3 and CYP3A5*5 are clinically important intronic SNPs [129]. 
CYP3A5*3 is the most common polymorphism seen in CYP3A5. This intronic 
SNP causes a splice variant with integration of a portion of intron 3. This leads to 
a frameshift and premature termination. This deleterious SNP is more commonly 
found in Caucasians and Asians, however, Africans more often express the 
functional, wild-type, enzyme [100, 133]. CYP3A5*5 causes a change in a base 
in the splicing donor site and results in truncated protein [129, 134]. 
 
Resequencing of CYP3A5 in CSKT populations resulted in identification of 10 
SNPs; 1 was novel and found at a low frequency. Other major identified SNPs 
are listed in Table 1.8. CYP3A5*3 was found at frequency of 92.47%, similar to 
Caucasians (Table 1.9). This results in 86% of the CSKT population as 
homozygous for CYP3A5*3, 14% are heterozygous individuals, and zero were 
homozygous for CYP3A5*1 (wild-type).   
 
Overall, CYP3A4 and CYP3A5 exhibit a high level of linkage. However, there 
was a break in the linkage between CYP3A4*1G and CYP3A5*1 (0.158 LD). The 
clinical relevance of this linkage will be explored in following section, Implications. 
 
1.C.iv. Implications 
Despite novel SNPs found in CYP2C9, CYP2D6, CYP3A4, and CYP3A5, they 
are not expected to play a large role in interindividual variability because of their 
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low frequencies. Most common allele frequencies were found to be similar to 
those found in Caucasians. Although, one SNP, CYP3A4*1G, was found at a 
much higher frequency. CYP3A4*1G frequency is much more similar to 
Japanese and Chinese populations. However, unlike all other populations where 
CYP3A4*1G is found in high linkage with CYP3A5*1, CSKT has a novel break in 
the linkage between CYP3A4*1G and CYP3A5*1. In combination, the relatively 
common CYP3A4*1G (26.81% allele frequency) and the high frequency 
CYP3A5*3 (92.47% allele frequency) in the CSKT could have large clinical 
implications because CYP3A4*1G data suggest lower activity [116-120] and 
CYP3A5*3 encodes for a nonfunctional protein [100, 133]. Individuals carrying 
CYP3A4*1G and CYP3A5*3 could have severely diminished CYP3A activity.  
 
1.C.v. CYP3A4*1G Data 
CYP3A4*1G is an intronic SNP found within intron 10 [135]. Again, most data 
suggest diminished activity for CYP3A4*1G. There have been several studies 
investigating the effect of CYP3A4*1G on fentanyl consumption post 
gynecological surgery [116, 117, 119, 120]. Zhang et al. found a trend of 
decreased fentanyl consumption for CYP3A4*1G carriers [119], while Dong et al. 
found a statistical difference of decreased fentanyl consumption between only 
CYP3A4*1G/*1G status with both the heterozygote and wild-type [117]. Zhang et 
al., interestingly, found a significant decrease in fentanyl consumption for patients 
carrying both CYP3A4*1G/*1G and CYP3A5*3/*3 [116]. This haplotype is seen in 
high frequency within the CSKT and could change their drug metabolism. More 
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recently, Yuan et al. analyzed the effect of CYP3A4*1G on fentanyl consumption 
as well as plasma concentrations [120]. They found that patients who expressed 
CYP3A4*1G/*1G had statistically higher fentanyl plasma concentrations and 
required lower fentanyl doses than those who expressed heterozygote or wild-
type genotypes. All patients in all studies were female; CYP3A4 genotype could 
have a higher impact on females, because they are reported to express more 
CYP3A4 [136]. With higher metabolism rates due to more protein content, 
changes in activity can results in larger changes in metabolism rates.  
 
A trend of decreasing function of CYP3A4*1G was found when investigating its 
effect on atorvastatin efficacy [118]. A gene-dose effect was found on the mean 
reduction of serum total cholesterol after atorvastatin treatment. However, this 
effect was not seen after simvastatin treatment, suggesting potential substrate-
specific effects. 
 
There are also a few studies that suggest CYP3A4*1G is a gain-of-function SNP. 
Miura et al. found that tacrolimus pharmacokinetics were significantly altered in 
patients carrying CYP3A4*1G and were CYP3A5 expressers; these patients had 
lower exposures and initial concentrations [137]. Zuo et al. also found this same 
effect. Patients carrying CYP3A4*1G and CYP3A5*1 had the highest tacrolimus 
clearance than other haplotypes. Also, CYP3A4*1G carriers and CYP3A5 
nonexpressers also had higher clearance than those expressing CYP3A4*1/*1 
and CYP3A5*3/*3 [138]. He et al. investigated the effect of CYP3A4*1G on 
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coronary heart disease (CHD) risk. Using a multivariate regression, they found 
that those who express CYP3A4*1G/*1G are at increased risk of CHD. The 
authors suggest that CYP3A4*1G is a gain of function. They argue that because 
CYP3A4 metabolizes estrogen, and estrogen is protective against CHD, that 
those who carry CYP3A4*1G must metabolize estrogen more quickly [139]. 
However, no probe drugs were used to actually assay CYP3A4*1G clearance. 
Another study, looking at CYP3A4*1G effect on risperidone metabolism, found 
no significant difference between plasma risperidone concentrations [140]. 
However, those expressing CYP3A4*1G/*1G did have much lower plasma levels. 
This study performed a Kruskal-Wallis analysis between all three genotypes 
groups. As in other studies, perhaps they would have found significance if they 
had grouped CYP3A4*1/*1 with CYP3A4*1/*1G and analyzed their plasma 
concentrations with CYP3A4*1G/*1G. Because risperidone is mainly metabolized 
by CYP2D6, the authors suggest that changes in CYP3A4 function would be of 
greater impact in those who are CYP2D6 poor metabolizers. CYP2D6 was not 
genotyped, which again, may have resulting in CYP3A4*1G significance when 
CYP2D6 genotype was accounted for. 
 
The combined data suggest a possible substrate-dependent effect of 
CYP3A4*1G. However, most data do indicate CYP3A4*1G results in decreased 
clearance. More research needs to be done to identify the effect of CYP3A4*1G 
as well as when inherited with CYP3A5*3/*3. 
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1.D. CYP3A Subfamily 
The CYP3A subfamily comprises four functional genes, CYPs 3A4, 3A5, 3A7, 
and 3A43, as well as two pseudogenes [129, 141]. All six genes are located 
inline with one another on chromosome 7 [129]. This subfamily shares many 
substrates but differ in tissue expression [34, 46, 129]. CYP3A4 metabolizes 
around 50% of drugs currently on the market and could, therefore, be considered 
one of the most important drug metabolizing enzymes (Table 1.1) [3, 34, 36, 46, 
129, 142-144]. Common SNPs in CYP3A5 encode for deleterious protein and, 
therefore, is variably expressed. CYP3A7 is expressed in fetal livers up until 
about 6 months of age. However, 10% of adult livers continue to express 
CYP3A7 and can contribute up to almost a quarter of total CYP3A content, which 
can contribute to clearance [145-147]. CYP3A7 expression into adulthood exists 
more in Japanese populations, with 3A7 accounting for up to 40% of 3A content 
[147]. CYP3A43 has been found in several tissues, however, at very low 
quantities. Also, it exhibits reduced activity towards testosterone, so it is not 
expected to play much of a role in xenobiotic metabolism [148].  
 
1.D.i. CYP3A4 
The CYP3A4 gene is 27kb and includes 13 exons and 12 introns. The gene 
encodes for a 57 kDa protein made up of 502 amino acids [57, 89, 149, 150]. 
Substrates of CYP3A4 are large and lipophilic [49]. CYP3A4 can metabolize a 
wide range of structural substrates due to its large and flexible binding pocket 
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[151, 152]. It has been known to bind multiple substrates at once which can 
cause increased or decreased product formation [153]. 
 
1.D.ii. CYP3A4 Variability 
It has been estimated that 90% of CYP3A4 interindividual variation is due to 
genetic factors [154]. Variability in CYP3A4 expression can cause a dramatic 
clinical effect due to the large number of substrates [30]. There is large 
interindividual variability seen in CYP3A4 expression, up to a 40-fold change 
[112, 155, 156]. However, most populations tend to lie within a 4- to 6-fold 
variation [106, 156-158]. Genetic variants do not account for all the variability, 
however, there are numerous factors that need to be considered [34, 129]. There 
have been over 20 variants reported that can explain for some variation. Also, 
CYP3A4 can be induced, through increased transcription, by certain xenobiotics, 
such as rifampicin, barbiturates, carbamazepine, glucocorticoids, and St. John’s 
Wort [34, 36, 46, 159]. CYP3A4 can also be inhibited by various xenobiotics. 
Ketoconazole, saquinavir, fluoxetine, and grapefruit juice have been reported to 
as inhibitors. Potent inhibitors can cause plasma levels of the drug to increases 
20-fold [34, 36, 160]. CYP3A4 is the only P450 that is expressed at different 
levels between sexes, with women expresses up to 2-fold more protein than men 
[136]. Finally, some interindividual variation may exist due to hormonal regulation 
of CYPs. Hormones can be endogenously circulating or present in diet [28]. All 
these factors can make determining genotype-phenotype correlations difficult.  
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1.D.iii. CYP3A4 Phenotypes 
Phenotypes seen from variation in CYP3A4 are unimodal, unlike what is seen in 
CYP2D6. In vivo treatment with midazolam resulted in outliers exhibiting higher 
clearances [158]. However, when treated with nifedipine, outliers were present 
with lower clearances [161]. This unimodal distribution suggests that no single 
factor can be used to predict CYP3A4 phenotype [30]. 
 
1.D.iv. CYP3A5 
CYP3A5 has 13 exons and is made up of 502 amino acids [32, 162]. Unlike 
CYP3A4, CYP3A5 is not markedly induced [163]. However, CYP3A5 is 
polymorphic with the most common SNP encoding for deleterious protein [164]. 
 
1.D.v. CYP3A5 Phenotypes 
In individuals who express wild-type CYP3A5 enzyme, CYP3A5 can make up 
50% of CYP3A content [100]. This can result in large interindividual variability in 
CYP3A metabolism; those carrying the CYP3A5*3/*3 genotype metabolize 
midazolam at less than half the rate of those carrying at least one CYP3A5*1 
functional allele [100, 156]. Due to the dramatic decrease in activity, CYP3A5 
genotype has been correlated with statin treatment side effects[165].  
 
1.D.vi. CYP3A4 and CYP3A5 Linkage Disequilibrium 
CYP3A4 and CYP3A5 are found in a high degree of linkage disequilibrium in 
Caucasian and Asian populations with the most common haplotype being 
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CYP3A4*1 and CYP3A5*3 [3]. Caucasians also exhibit linkage disequilibrium 
between CYP3A4*1B and CYP3A5*1 [100, 106]. It is hypothesized that the two 
haplotypes could result in similar activity; the two alleles compensate for one 
another. African populations have very diverse haplotypes with no significant 
degree of linkage disequilibrium seen [3], however, they are more likely to carry 
both the CYP3A4*1B and the CYP3A5*1 alleles [100, 166]. 
 
 
1.E. Specific Aims 
The objective of this project is to determine the functional consequence of the 
CYP3A4*1G genetic variant using in vitro methods. The specific goals of Aim 1 
was to use immortalized human lymphocytes with differing CYP3A4 genotypes 
(CYP3A4*1/*1, CYP3A4*1/*1G, and CYP3A4*1G/*1G) to analyze the effect of 
CYP3A4*1G on relative mRNA content, protein content, and enzyme activity. 
Aim 2 used human liver microsomes to, again, determine the effect of 
CYP3A4*1G on protein content and enzyme activity.  
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Table 1.1. List of CYP2C9, CYP2D6, and CYP3A4/5 Common Substrates, 
Inhibitors, and Inducers  
 
 Substrates Inhibitors Inducers 
CYP2C9 ibuprofen 
phenytoin 
tolbutaminde 
S-warfarin 
 
amiodarone 
fluconazole 
fluvoxamine 
fluoxetine 
sulfaphenazole 
 
rifampin 
CYP2D6 
 
atomexetine 
bufuralol  
debrisoquine 
desipramine 
dextromethorphan 
bupropion 
fluoxetine  
paroxetine 
quinidine 
 
CYP3A4/CYP3A5 buspirone 
erythromycin 
felodipine 
dextromethorphan 
lovastatin 
midazolam 
nifedipine 
simvastatin 
terfenadine 
testosterone 
triazolam 
 
azamulin 
clarithromycin 
erythromycin 
fluconazole 
grapefruit juice 
indinavir 
itraconazole 
ketoconazole 
ritonavir 
saquinavir 
troleandomycin 
verapamil 
carbamazepine 
phenytoin 
rifampin 
St. John’s wort 
 
This list is not intended to be inclusive. Adapted from FDA website “Drug Development 
and Drug Interactions: Table of Substrates, Inhibitors and Inducers.”  
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Table 1.2. Major CYP2C9 Alleles 
 
Allele Nucleotide Change Protein Change Activity Change 
CYP2C9*2 (rs1799853) 430C>T R144C decreased 
CYP2C9*3 (rs1057910) 1075C>C I359L decreased 
Adapted from Fohner, et al, 2013 [90, 167, 168]. 
 
 
Table 1.3. CYP2C9 Allele Frequencies 
 
Allele CSKT CEU YRI JPT CHB Canadian 
Inuit 
Canadian 
First 
Nation 
Central 
America 
(Tepehuano/ 
Mestizos) 
rs4918758 25.0 35.8 30.1 41.3 33.7    
CYP2C9*2 5.17 10.4 0 0 0 0 3.0 1 - 7 
CYP2C9*3 2.69 5.8 0 2.3 4.7 0 6.0 1.5 
rs28371689 30.77        
rs1057911 2.7 5.8 0 3.4 4.4    
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap 
populations: CEU = Utah residents with ancestry from northern and western Europe 
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT = 
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China 
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90]. 
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Table 1.4. Major CYP2D6 Alleles  
 
Allele Nucleotide Changes Protein Effect Phenotype 
CYP2D6*1 Wild-type None EM 
CYP2D6*2 2850C>T; 4180G>C R296C; S486T  
CYP2D6*3 2549delA Frameshift PM 
CYP2D6*4 100C>T; 1846G>A; 4180 G>C P34S; splicing defect; 
S486T 
PM 
CYP2D6*5 Gene Deletion Gene deletion PM 
CYP2D6*9 2615delAAG K281del IM 
CYP2D6*10 100C>T; 4180G>C P34S; S486T IM 
CYP2D6*17 1023C>T; 2850C>T Amino Acid Substitution IM 
CYP2D6*28 19G>A; 1704C>G; 2850C>T; 
4180G>C 
V7M; Q151E; R296C; 
S486T 
ND 
CYP2D6*33 2483G>T A237S EM 
CYP2D6*35 31G>A; 2850C>T; 4180G>C V11M; R296C; S486T EM 
CYP2D6*41 2850C>T; 2988G>A; 4180G>C R296C; splicing defect; 
S486T 
IM 
Phenotypes denoted as: PM = Poor Metabolizer; IM = Intermediate Metabolizer. 
Adapted from Fohner, et al., 2013 [90]. 
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Table 1.6. Major CYP3A4 alleles 
 
Allele  Nucleotide 
Change 
Protein Effect Change in 
Activity 
CYP3A4*1B (rs2740574) -392A<G promoter decreased 
CYP3A4*1G (rs2242480) 20230G>A intronic decreased 
CYP3A4*2 (rs55785340) 15713T>C Ser222Pro decreased 
CYP3A4*3 (rs4986910) 23171T>C Met445Thr none 
CYP3A4*8 (rs72552799) 13908G>A Arg130Gln decreased 
CYP3A4*12 (rs12721629) 21896C>T Leu373Phe both 
CYP3A4*13 (rs4986909) 22026C>T Pro416Leu decreased 
CYP3A4*15A (rs4986907) 14269G>A Arg162Gln nonfunctional 
CYP3A4*17 (rs4987161) 15615T>C Phe189Ser both 
CYP3A4*18 (rs28371759) 20070T>C Leu293Pro both 
CYP3A4*22 (rs35599367) 15389C>T intronic decreased 
Adapted from Fohner, et al, 2013 [90, 135, 168]. 
 
 
Table 1.7. Major CYP3A4 Allele Frequencies  
 
Allele CSKT CEU YRI JPT CHB Central America 
(Tepehuano/ 
Mestizos) 
CYP3A4*1B 2.20 3.0 72.0 0 0.3 8.0 – 8.8 
CYP3A4*1G 26.81 8.3 88.9 29.7 28.0  
CYP3A*2 0 0 0 0 0  
CYP3A4*3 0 1.2 0 0 0  
CYP3A4*8 0 0 0 0 0  
CYP3A4*12 0 0 0 0 0  
CYP3A4*13 0.60 0.4 0 0.6 1.2  
CYP3A4*15A 0.68 0 2.84 0 0  
CYP3A4*17 0 0 0 0 0  
CYP3A4*18 0 0 0 1.7 0  
CYP3A4*22 2.44 5.29 0 0 0  
rs2687116 2.27 1.8 74.4 0 0  
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap 
populations: CEU = Utah residents with ancestry from northern and western Europe 
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT = 
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China 
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90, 121, 169]. 
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Table 1.8. Major CYP3A5 Alleles 
 
Allele Nucleotide 
Change 
Protein Effect Change in Activity 
CYP3A5*3 (rs776746) 6986A>G intronic nonfunctional 
CYP3A5*6 (rs10264272) 14690G>A truncation nonfunctional 
CYP3A5*7 (rs76293380) 27131_27132insT frameshift nonfunctional 
rs15524 31611T>C 3’ UTR  
Adapted from Fohner, et al, 2013 [90, 135, 168].  
 
 
Table 1.9. Major CYP3A5 Allele Frequencies 
 
Allele CSKT CEU YRI JPT CHB 
CYP3A5*3  92.27 94.1 15.0 73.3 66.3 
CYP3A5*6 0 0 16.8 0.6 1.2 
CYP3A5*7 0 0 0 0 0 
rs15524 10.64 4.0 72.6 28.5 33.7 
CSKT = Confederated Salish and Kootenai Tribes (n=188 chromosomes). HapMap 
populations: CEU = Utah residents with ancestry from northern and western Europe 
(n=120 chromosomes); YRI = Yoruba in Ibadan, Nigeria (n=120 chromosomes); JPT = 
Japanese in Tokyo, Japan (n=90 chromosomes); CHB = Han Chinese in Beijing, China 
(n=90 chromosomes). Adapted from Fohner, et al., 2013 [90, 121, 169]. 
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Figure 1.1. Cytochrome P450 Cycle. Adapted from [170]. 
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Chapter 2: Lymphocytes as Surrogates of CYP3A Drug 
Metabolism 
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2.A. Introduction 
CYP3A4 is responsible for the metabolism of 50% of drugs currently on the 
market [129, 142, 143]. It is reported that 66 - 90% of the interindividual variability 
in CYP3A4 activity is a result of genetic variability [154]. While there are many 
identified SNPs, several do not have conclusive evidence linking them to the 
interindividual change [168]. CYP3A4*1G is an SNP located within intron 10 
(20230G>A) and has conflicting reports of its impact on CYP3A4 activity. Most 
reports show a decrease in activity [116-120], however, some show an increase 
in function [137-139]. 
 
Genetic variants can be measured in vivo, where CYP activity is measured via 
administration of probe drugs or radiolabeled drugs [171, 172]. Probe drugs are 
metabolized by a single drug-metabolizing enzyme and are administered to 
identify the function of that enzyme, or the change in function of the enzyme due 
to the presence of a SNP. Plasma concentrations of the probe drug and 
metabolites are measured to estimate various pharmacokinetic parameters [172]. 
Also, one could measure CYP changes in activity, protein, and mRNA levels 
within liver hepatocytes or microsomes after performing a liver biopsy [173, 174]. 
However, both methods present some considerable disadvantages. Probe drug 
administration creates the risk of adverse events, multiple blood draws and urine 
collection, length of time needed to collect samples from patient, and the 
associated high cost [175]. Liver biopsies are not routinely performed, especially 
for the purpose of the phenotyping a patient [173]. These substantial 
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disadvantages associated with in vivo phenotyping presents a large barrier in 
clinical practice as well as research. 
 
Because of some of the challenges associated with existing phenotyping 
methods, there is increased interest in using a more readily available tissue such 
as peripheral blood cells. These cells could be used as surrogate markers of 
drug metabolism or changes in drug metabolism. Peripheral blood cells are made 
up of red blood cells, white blood cells, and platelets. White blood cells are made 
in lymphoid tissues and include several subsets of cells: neutrophils, eosinophils, 
basophils, monocytes, and lymphocytes. Lymphocytes are responsible for 
recognizing foreign antigens and mounting a response [176]. There are several 
advantages to measuring CYP activity in lymphocytes: no need for probe drug 
administration, less invasive sampling, less time involved for the patient, as well 
as less expensive to test [175]. Several CYPs have been measured in 
lymphocytes, including CYP3A4 [177]. However, there are conflicting reports in 
literature of the consistency in measuring CYP3A4 activity and mRNA levels and 
its correlation to liver activity and expression [173, 175, 178-183]. 
 
The goal of this study was to determine the functional consequences of the 
genetic variant CYP3A4*1G using lymphocyte cell lines that are wild type, 
heterozygote, and homozygote for the CYP3A4*1G genotype. CYP3A4*1G 
functional consequence in lymphocytes was assessed by measuring 1) mRNA by 
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quantitative PCR, 2) protein levels by immunoblot detection, and 3) CYP3A4 
activity using the substrate luciferin IPA. 
 
2.B. Materials and Methods 
2.B.i. Cells 
B-lymphocytes were ordered from the National Human Genome Research 
Institute Sample Repository for Human Genetic Research through the Coriell 
Institute for Biomedical Research. Lymphocytes were selected based on 
CYP3A4 and CYP3A5 genotype: CYP3A4*1/*1, CYP3A4*1/*1G, and 
CYP3A4*1G/*1G; all samples were CYP3A5*1/*1. All samples were from 
females. Cells were maintained in RPMI Medium 1640 with 2mM L-glutamine 
and 15% FBS at 37°C and 5% CO2. They were split to a density of 200,000 
viable cells/mL every third day. 
 
2.B.ii. RNA Isolation and cDNA synthesis 
RNA was isolated using the PureLink® RNA Mini Kit (Life Technologies, 
Carlsbad, CA) and RNA concentration and quality was measured on a Nanodrop 
spectrophotometer. PureLink® DNAse Treatment (Life Technologies) was used 
during RNA extraction to digest any DNA. cDNA was immediately synthesized 
using the High Capacity RNA-to-cDNA™ Kit (Applied Biosystems®, Carlsbad, 
CA) on a C1000 Thermocyclyer (Bio-Rad, Hercules, CA). Samples were not 
frozen and immediately underwent quantitative PCR.  
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2.B.iii. Quantitative Real-time PCR 
CYP3A4, CYP3A5, β-actin, and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA were measured using TaqMan® Gene Expression Assay 
(Applied Biosystems®). Primer/probe pairs were: CYPA4 Hs00604506_m1; 
CYP3A5 Hs01070905_m1; β-actin H99999903_m1; GAPDH Hs03929097_g1. 
Taqman® probes had a reporter dye, FAM™, on the 5’ end and a nonfluorescent 
quencher (TAMRA™) on the 3’ end. TaqMan® Universal Master Mix II, with UNG 
was used to perform amplifications. TaqMan® probe identification and amplicon 
length as well as exon location are defined in Table 2.1. All amplicons produced 
are relatively short and are not expected to PCR efficiency. Probes for CYP3A4 
and CYP3A5 span exons, so no genomic DNA will be amplified. cDNA template, 
200 ng, underwent cycling conditions of 1 cycle at 50°C for 2 min, 1 cycle of 95°C 
for 10 min, then 50 cycles of denaturation at 95°C for 15 sec and 
annealing/elongation at 60°C for 1 min on an Mx3000P qPCR system (Agilent 
Technologies, Santa Clara, CA). Each amplification was performed in 
quadruplicate at two separate times with independent RNA isolations. Data was 
normalized to housekeeping gene (ΔCt) by subtracting its Ct from the Ct of the 
CYP3A4/5. Ct was defined as 10 standard deviations above average background 
level. Reporter signal was normalized to a passive reference dye, ROX™, 
included in the master mix. 
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2.B.iv. CYP3A4 Protein Quantitation in Lymphocytes  
Protein quantitation in lymphocyte was performed by immunoblot. Total protein 
(10 µg) of cell lysate was added and resolved on a Tris-Hepes NH 4-20% 
(NuSep, Lane Cove, Australia). Protein was transferred to nitrocellulose 
membranes and blocked with 5% milk for 1 hour. The membrane incubated with 
primary anti-CYP3A4 antibody (Abnova, Taipei City, Taiwan) (1:1,000 dilution) on 
a rocker overnight at 4°C. Secondary anti-mouse antibody was added (1:25,000 
dilution) for 1 hour at room temp. Membrane was developed using the West 
Femto Kit (Thermo Scientific™, Waltham, MA) and imaged on a using an LAS-
3000 camera (Fujifilm, Minato, Tokyo). 
 
2.B.v. CYP3A4 Protein Quantitation in Human Liver Microsomes  
Protein quantitation in human liver microsomes was performed by immunoblot. 
Total protein (10 µg) were added per HLM sample and resolved on a Tris-Hepes 
NH 4-20% gel (NuSep) Protein was transferred to nitrocellulose membranes and 
blocked with 5% milk for 1 hour. The membrane incubated with primary anti-
CYP3A4 antibody (Abnova) (1:1,000 dilution) on a rocker overnight at 4°C. 
Secondary anti-mouse antibody was added (1:25,000 dilution) for 1 hour at room 
temp. Membrane was developed using the West Femto Kit (Thermo Scienctific™) 
and imaged on an LAS-3000 camera (Fujifilm). 
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2.B.vi. CYP3A4 Activity in Lymphocytes  
CYP3A4 activity was assessed in lymphocytes using P450-Glo™ assay system 
(Promega, Madison, WI). Lymphocytes were counted in serum-free media and 5 
x 104 – 5 x 106 cells in suspension were placed into 1.5 ml eppendorf tubes. An 
equal volume of 2x P450-Glo™ substrate (Lucierin IPA) in serum free media was 
added to cell suspension. Tubes were incubated at 37°C and 5% CO2. An equal 
volume of Luciferin Detection Reagent was added and tubes were placed on an 
orbital shaker for 15-20 min at room temp. Solution was transferred to a white, 
untreated 96-well plate and luminescence detected on a SynergyMX microplate 
reader (Biotek, Winooski, VT) with an integration time of 1 second/well.  
 
2.B.vii. Data Analysis 
A Tukey’s post hoc test was completed to determine differences in the qPCR 
ΔCts between lymphocyte cell lines, α=0.05 (KaleidaGraph, Reading, PA). 
 
2.C. Results 
2.C.i. CYP3A4 mRNA Expression in Lymphocytes 
All genes of interest were detected in all three lymphocyte cell lines, although, 
CYP3A4 mRNA levels were very low as demonstrated by the high Ct values 
(Table 2). Representative quantitative PCR traces of each cell line are shown in 
Figure 2.1. The Cts of all genes are reported in Table 2.2 and ΔCts, CYP3A4 and 
CYP3A5 normalized to housekeeping genes, are reported in Figure 2.3. ΔCts 
show that the order of the CYP3A4 expression is as follows: CYP3A4*1/*1G > 
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CYP3A4*1G/*1G > CYP3A4*1/*1. There is statistical significance between all 
three cell lines (normalizing to β-actin: *1/*1 and *1/*1G p<0.0001; *1/*1 and 
*1G/*1G p=0.002; *1/*1G and *1G/*1G p=0.031 and normalizing to GAPDH: 
*1/*1 and *1/*1G p<0.0001; *1/*1 and *1G/*1G p=0.045; *1/*1G and *1G/*1G 
p=0.002). With respect to CYP3A5 expression levels, CYP3A4*1/*1G also 
expresses the most CYP3A5. The *1/*1G genotype expresses more CYP3A5 
than the *1/*1 genotype, after normalizing to both β-actin and GAPDH, p<0.0001 
for all comparisons. However, there is no significance between the CYP3A5 
expression levels when controlling for either housekeeping gene between the 
CYP3A4*1G/*1G and CYP3A4*1/*1 genotypes (β-actin p=0.63; GAPDH p=0.4).  
 
To show that CYP3A4 was amplified in qPCR, and the high Ct was not due to 
primer/probe degradation, the amount of cDNA added to each reaction was 
diluted. Instead of adding 200 ng of total RNA to each reaction, 25 ng of total 
RNA was added. Figure 2.3 shows the qPCR traces of the template dilution. The 
diluted total RNA samples have a higher Ct value indicating less CYP3A4 mRNA 
in the sample. Table 6 shows the Ct values of each gene for the different 
amounts of total RNA added as well as the ratio of Cts for 200 ng to 25 ng. These 
ratios were similar across genes, confirming that the Cts measured are not due to 
probe degradation.  
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2.C.ii. CYP3A4 Protein Expression in Lymphocytes 
Immunoblots of each lymphocyte cell line were performed to quantify CYP3A4 
protein content. In contrast to the qPCR data, western blot quantification (Figure 
2.4) shows that CYP3A4*1G/*1G has the most expression, followed by 
CYP3A4*1/*1G. Wild-type CYP3A4 had no detectable protein, however, a high 
molecular weight band was detected. To understand this high molecular weight 
band, we ran another immunoblot in human liver microsomes of the same 
genotypes (Figure 2.4). The high molecular weight band was not detected in any 
genotype of the human liver microsomes and it appears to be specific to 
lymphocytes. 
 
2.C.iii. CYP3A4 Activity in Lymphocytes 
Next, CYP3A4 activity in lymphocytes was measured. Cells were first incubated 
with 3 µM substrate for 15 min with zero activity measured. Next, time was 
increased to 1 hour incubation at the same substrate concentration and, again, 
measured zero activity. Finally, cells were treated with 25 µM substrate for 3 
hours; the rate measured was negligible.  
 
2.D. Discussion 
There is interest in finding a more accessible tissue as a surrogate of drug 
metabolism in the liver. Blood sampling is minimally invasive, low risk, and 
relatively unlimited. However, CYPs are not highly expressed within lymphocytes 
and there are several contradicting studies as to their metabolic relevance. Our 
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goal was to establish whether immortalized lymphocytes, with defined CYP3A4 
and CYP3A5 genotypes, could be used to determine the functional consequence 
of the CYP3A4*1G SNP. 
 
Several groups have been able to quantify CYP3A4 in lymphocytes. Sempoux et 
al. and Starkel et al. showed that CYP3A proteins were detectable in B-
lymphocytes by immunoblot and or immunohistochemistry [184, 185]. Nakamoto 
et al. were able to detect CYP3A4 mRNA in all samples of lymphocytes (n=8) by 
quantitative competitive (QC) RT-PCR. They were also able to measure a 
statistically significant level of induction after oral administration of rifampin. 
Along with an increase of mRNA content, this group also found an increase in the 
ratio 6β-hydroxycortisol to cortisol, indicating an increase in CYP3A4 liver activity. 
These data imply that lymphocytes can indeed be used as a surrogate for liver 
activity [180]. However, this group did not use primers that spanned exons, 
causing amplification of any DNA present in the sample. This could result in more 
CYP3A4 measured than is actually present as cDNA. Krovat et al. and 
Nowakowski-Gashaw et al. were able to detect CYP3A4 in lymphocytes using 
QC-PCR [182, 186]. Gashaw et al. was also able to measure CYP3A4 
expression in all samples and also found a weak, but significant, correlation 
between mRNA content in lymphocytes with alprazolam clearance [173]. 
 
Some groups have been able to detect CYP3A4 but were unable to correlate 
levels of expression with CYP3A4 function in the liver. Finnstrom et al. reported 
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measuring CYP3A4 expression at relatively high levels. They used qPCR with 
16.7 ng total RNA and a Ct cutoff value of 38, which corresponds to 1000 
molecules. Most lymphocyte traces had Cts between 33 and 37, however, they 
did not show housekeeping, normalizing gene traces. They were unable to find a 
correlation between liver and lymphocyte CYP3A4 expression [179]. Haas et al. 
also were able to measure CYP3A4 mRNA in all samples but found a poor 
correlation between lymphocyte mRNA and total body enzyme function. However, 
Koch et al. and Siest et al. were unable to detect CYP3A4 in lymphocytes and 
used up to 40 ng of total RNA per reaction [178, 181]. Several of these studies 
measured CYP3A4 in lymphocytes after induction. Weak correlation, if any was 
found, possibly due to the mechanism of induction. Rifampin activates pregnane 
X receptor (PXR), which binds to the promoter of CYP3A4. However, PXR 
expression is tissue-specific and also exhibits interindividual variability [175]. This 
could explain the negative findings after induction. None of these studies 
investigated the impact of CYP3A4 genotypes and its expression in lymphocytes 
with CYP3A4 liver function.  
 
We were able to measure the relative quantities of CYP3A4 in all lymphocyte cell 
lines. The Ct values of CYP3A4 indicate very low levels present in lymphocytes. 
CYP3A4*1/*1G heterozygotes had not only the most CYP3A4 expression, but 
also the most CYP3A5 expression, which all had the same genotype. Therefore, 
CYP3A4 content between cell lines, although significant, but doesn’t appear to 
be meaningful. One would expect to see a gene-dose relationship between cell 
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line with the heterozygote cells expressing an intermediate level of mRNA, 
making it impossible for the heterozygotes to express the most CYP3A4. 
Therefore, there is some other unknown mechanism, other than the CYP3A4*1G 
genotype, causing the CYP3A4*1/*1G cells to express the most CYP3A4 and 
CYP3A5. Perhaps, there are unknown SNPs within the regulation pathway of 
CYP3A enzymes that is causing the upregulation of both CYP3A4 and CYP3A5, 
for instance, PXR. 
 
We are confident that all Cts measured are real and not due to primer/probe 
degradation. Figure 2.3 shows the qPCR curve shift to the right when less total 
RNA was added. Also, the ratio Cts of the 200 ng total RNA to 25 ng total RNA is 
similar across all genes. Again, indicating that measured Cts are of templates 
and changes in Cts are due to changes in starting template.  
 
In contrast to the qPCR data, protein quantification by immunoblot actually shows 
CYP3A4*1G/*1G has the highest protein content, followed by CYP3A4*1/*1G, 
and not detectable in CYP3A4*1/*1. This data is more in line with the gene-dose 
theory with the heterozygotes expressing an intermediate amount of protein. 
Interesting, the wild-type lymphocytes exhibit a larger molecular weight band that 
is present at lower levels in the heterozygote and not present in the *1G 
homozygote. This led us to perform another immunoblot with a more relevant 
tissue, human liver microsomes (HLM), to see if this high molecular weight band 
is also present. This band was not seen in any genotype of HLM samples and 
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appears to be specific to the lymphocytes. It is unclear at this time what this band 
is or its clinical relevance, if any. However, it is clear that it is not due to the gene 
status of CYP3A4. 
 
We were unable to measure the activity of CYP3A4 within lymphocytes using a 
highly sensitive, luminescent method. Cells are incubated with luciferin IPA, 
which creates luminescence after it is metabolized by CYP3A4, upon addition of 
the detection reagent. This is a sensitive method to detect minimal activity within 
the lymphocytes. However, regardless of length of incubation or the 
concentration of substrate, negligible, if any, activity was measured. 
 
Our study shows that lymphocytes do not appear to be a good source to 
measure CYP3A4 activity in vitro. Our goal was to use lymphocytes as a 
surrogate human tissue to evaluate the effects of the CYP3A4*1G SNP, however, 
measurements of CYP3A4 mRNA and protein content and CYP3A4 activity in 
lymphocytes suggest that they are not a reliable surrogate for liver enzyme 
content and function. Our data confirm that lymphocytes are not able to be used 
to identify changes in enzymes due to CYP3A genetic variation.  
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Table 2.1. TaqMan®  Probe Information 
 
Protein Amplicon Length Location (exons) 
CYP3A4 
(Hs00604506_m1) 
119 2-3 
CYP3A5 
(Hs01070905_m1) 
101 2-3 
β-actin 
(Hs99999903_m1) 
171 1 
GAPDH  
(Hs03929097_g1) 
58 8 
Primer/probes pairs where ordered from Applied Biosystems®. TaqMan® Gene 
Expression Assay was used with a reporter dye, FAM™ on the 5’ end and a 
nonfluorescent quencher (TAMRA™) located on the 3’ end.  
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Table 2.2. Cts by Genotype 
 
 CYP3A4 CYP3A5 β-Actin GAPDH 
CYP3A4*1/*1 38.95 ± 0.616 34.02 ± 0.189 14.81 ± 0.147 15.84 ± 0.167 
37.68 ± 0.259 33.85 ± 0.250 13.54 ± 0.015 14.76 ± 0.059 
CYP3A4*1/*1G 38.33 ± 0.288 33.06 ± 0.126 16.68 ± 0.224 16.51 ± 0.213 
36.64 ± 0.387 30.61 ± 0.214 13.84 ± 0.282 14.86 ± 0.577 
CYP3A4*1G/*1G 38.85 ± 0.315 34.80 ± 0.355 16.07 ± 0.125 16.32 ± 0.200 
37.29 ± 0.367 34.27 ± 0.161 14.05 ± 0.139 14.78 ± 0.154 
Two qPCR runs were completed per cell line (each row represents one run). Ct is 
defined as ten standard deviations above the average background level. 
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Table 2.3. Cts of Template Dilution 
 
 CYP3A4 CYP3A5 GAPDH β-actin 
200 ng 38.91 ± 0.54 34.32 ± 0.28 15.79 ± 0.11 20.36 ± 0.11 
25 ng 44.68 ± 1.60 39.46 ± 0.84 20.05 ± 0.21 24.89 ± 0.09 
Ratio 200 ng/25 ng 0.871 0.870 0.788 0.818 
Each qPCR run in quadruplicate. Ct is defined as ten standard deviations above the 
average background level. 
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 A. B. 
  
 C. 
 
 
Figure 2.1. qPCR Traces of Lymphocytes. A. CYP3A4*1/*1 lymphocytes B. 
CYP3A4*1/*1G lymphocytes C. CYP3A4*1G/*1G lymphocytes. Traces (n=4) are 
representative. Solid circles are CYP3A4 amplicons, empty circles are CYP3A5 
amplicons, solid triangles are β-actin amplicons, and empty triangles are GAPDH 
amplicons. Fluorescence (dRN) is the reporter signal normalized to a passive reference 
dye, ROX™.  
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Figure 2.2. CYP3A4 and CYP3A4 Normalized Expression Levels. Each gene is 
normalized to housekeeping genes, as denoted in the figure legend. Lower values 
correlate to more mRNA expression of the gene of interest (CYP3A4 or CYP3A5). 
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Figure 2.3. qPCR Traces of Template Dilution. qPCR traces of 200 ng (solid circles) 
and 25 ng (empty circles) of total RNA added per reaction. Fluorescence (dRN) is the 
reporter signal normalized to a passive reference dye, ROX™.  
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Figure 2.4. Immunoblot and Quantification CYP3A4 Protein. A. Lymphocyte 
CYP3A4 immunoblot. Standards lane 1 (10 ng), 2 (5 ng), 3(1 ng), 4 (0.5 ng), 5 (0.25 ng). 
Lymphocytes lanes 7 (CYP3A*1G/*1G), 8 (CYP3A4*1/*1G), and 9 (CYP3A4*1/*1). 
Negative control, Sf9 insect cells, lane 10.. B. CYP3A4 protein quantitation stratified by 
genotype of lymphocyte cell lines. C. HLM CYP3A4 immunoblot. Lanes 1 and 2 are 
CYP3A4*1G/*1G samples, lanes 3-7 are CYP3A4*1/*1G samples and lanes 8-11 are 
CYP3A4*1/*1 samples. Standards are in Lanes 13(1 ng), 14 (5 ng), and 15 (10 ng). 
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Chapter 3. Effect of the Genetic Variant CYP3A4*1G 
 in Human Liver Microsomes 
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3.A. Introduction 
CYP3A4 is drug-metabolizing enzyme highly expressed in the liver and intestine 
[97]. CYP3A4 metabolizes about 50% of all medications available on the market, 
comprised of more than 120 different drugs from therapeutic classes that include 
antihistamines, immunosuppressive agents, benzodiazepines, and HIV protease 
inhibitors [99, 131]. Up to 40-fold variability has been reported in interindividual 
CYP3A4 activity [112, 155, 156] and up to 90% is predicted to be due to genetic 
factors [154]. Because of the huge diversity of CYP3A4 substrates, genetic 
variability can have a large clinical impact in drug response and toxicity [30]. 
Pharmacogenomic studies aim to identify these genetic variations and determine 
their resulting changes in activity. 
 
Probe drug studies are the gold standard in in vivo phenotyping of 
pharmacogenetic variation as they provide direct predictions of alterations in 
pharmacokinetic parameters, however, these studies have considerable 
disadvantages (discussed earlier in Chapter 1 section A.ii.). Therefore, 
investigators also try to evaluate pharmacogenetic variation using in vitro 
methods [187, 188]. One of these widely accepted methods is using human liver 
microsomes (HLM) [189]. HLMs are generated from liver samples, obtained by 
liver biopsies or organ donation. Liver samples undergo several cycles of 
homogenation and centrifugation to form vesicles from isolated endoplasmic 
reticulum. Because CYPs are microsomal proteins, HLMs contain concentrated 
levels of CYPs. Liver microsomes enable one to make pharmacokinetic 
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estimations (rate of metabolism, intrinsic clearance) that are scalable to whole 
liver and whole body predictions, without the need to administer medications in 
vivo and gather blood and urine samples. For instance, HLMs were first identified 
to give good predictions of intrinsic clearance in rats [41, 190-192]. Correlations 
were soon made between clearances measured in HLMs and those measured in 
an in vivo pharmacokinetic study [187, 193, 194]. In order to best estimate 
intrinsic clearance, it is important to maintain incubations conditions similar to 
those seen in vivo. Specifically, incubation times need to be such that product 
formation is linear (initial rate is constant) over the duration and drug 
concentrations are comparable to clinical concentrations [187]. Scaling from 
HLMs to whole body deviate the most when metabolism occurs in organs other 
than the liver, for instance, the intestines, or when metabolism occurs by routes 
other than CYP oxidation [187, 195]. This scenario would lead to an 
underestimate of total clearance [187]. HLMs are commonly used in research as 
well as drug development [196]. They are inexpensive, convenient, readily 
available, and create reproducible data [197]. When stored at -80°C, microsomes 
retain their activity for years [198]. 
 
There are disadvantages to using microsomes as an alternative for in vivo data. 
Disease and medication histories of the subjects from whom the livers are 
obtained are often unknown or incomplete. Disease state, such as diabetes 
mellitus, can cause decreased CYP3A4 expression and activity [199]. Length of 
time before organ procurement can also affect CYP expression; increased 
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cytokine release, due to inflammation and infection, as well as decreased 
hormone secretion leads to down regulation of CYPs [30, 154, 200].  
Concurrent medications can cause inhibition or induction and need to be 
incorporated into data analysis. Also, organ collection protocols, tissue storage 
conditions, and microsomal preparations all can have an effect on microsomal 
enzyme activity. Because of this, it has reported that in vitro interindividual 
variability is larger than in vivo interindividual variability [129]. 
 
Our study aimed to investigate the any change in activity due to the CYP3A4*1G 
genetic variant in vitro using HLMs that have been previously genotyped. 
CYP3A4 activity in HLM was measured using a selective CYP3A4 substrate with 
minimal/no substrate overlap with CYP3A5. Our goal was to make genotype-
phenotype associations in the HLMs to assess CYP3A4*1G activity.  
 
3.B. Materials and Methods 
3.B.i. Human Liver Microsomes 
Human liver microsomes (n=324) were obtained from University of Washington, 
School of Pharmacy Human Liver Tissue Bank (Seattle, WA). The University of 
Washington made all human liver microsomes. Liver tissue was homogenized 
using a Bead Ruptor. Homogenate was centrifuged at 15,000g for 30 min. 
Centrifuge supernatant at 120,000g for 70 min. The pellet was resuspended in 
wash buffer and homogenized with a glass homogenizer and centrifuged at 
120,000 g for 70 min. Pellet resuspended in wash buffer with a glass 
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homogenizer and stored at -80°C. Livers were genotyped in Debbie Nickerson’s 
Laboratory in the Department of Genome Sciences University of Washington 
(Seattle, WA). Genotyping was determined via PGRNseq Platform (University of 
Washington). PGRNseq is a next-generation sequencing platform that 
sequences coding regions, adjacent noncoding regions, 2kb upstream, and 1kb 
downstream in 84 genes Very Important Pharmacogenes.  
 
3.B.ii. CYP3A4 Activity in Human Liver Microsomes 
CYP3A4 activity in HLMs (n=64) was determined with the P450-Glo™ kit 
(Promega) according to manufacturer’s specifications. Five µg of total protein 
were preincubated in microfuge tubes with 4x P450-Glo™ substrate (luciferin 
IPA) and KPO4 buffer for 10 min in a water bath at 37°C. An equal volume of 
2mM NADPH was added to initiate the reaction and HLMs were, again, 
incubated for 10 min in a water bath at 37°C. An equal volume of Luciferin 
Detection Reagent was added and tubes were placed on an orbital shaker for 15-
20 min at room temp. All incubations were completed in triplicate. Pooled HLMs 
were used as a positive control in every incubation set (in duplicate). Solution 
was transferred to a white, untreated 96-well plate and luminescence detected on 
a SynergyMX microplate reader (Biotek, Winooski, VT) with an integration time of 
1 second/well. Optimization of HLM incubation conditions was completed using 
pooled HLM (Xenotech, Lenexa, KS). 
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3.B.iii. CYP3A4 Protein Quantitation in Human Liver Microsomes 
Protein quantitation was performed by immunoblot. Total microsomal protein (10 
µg) was resolved on a Tris-Hepes NH 4-20% gel (NuSep). Protein was 
transferred to nitrocellulose membranes and blocked with 5% milk for 1 hour. The 
membrane incubated with primary anti-CYP3A4 antibody (Abnova) (1:1,000 
dilution) on a rocker overnight at 4°C. Secondary anti-mouse antibody was added 
(1:25,000 dilution) for 1 hour at room temp. Membrane was developed using the 
West Femto Kit (Thermo Scientific™) and imaged on an LAS-3000 camera 
(Fujifilm). 
 
3.B.iv. Data Analysis 
An ANOVA was performed to test the differences between the HLM genotypes in 
both activity and protein quantitation, α=0.05 (KaleidaGraph). A multivariable 
regression was completed to test the significance of each variable on CYP3A4 
activity. Variables tested were: protein content, genotype, age, gender, race, 
taking a 3A4 inducer, taking a 3A4 inhibitor, liver pathology, cause of death, 
height, weight, ICU time, liver ischemia, organ trauma, smoking status liver lab 
results, and pathology. Missing data was not included in the analysis (StatsPlus, 
Alexandria, VA) 
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3.C. Results 
3.C.i Optimization of Microsomal Incubation Conditions 
HLMs are precious samples, some with extremely limited protein, so we 
optimized the HLM assay using commercially available pooled HLMs (Figure 3.1). 
First, microsomal protein per incubation was titrated to determine the linear range 
of product formation (Figure 3.1A and 3.1B); we found that product formation was 
linear between 1.25 and 10 µg total protein per reaction. The substrate, luciferin 
IPA, is provided from Promega in 100% DMSO, however, DMSO is a known 
inhibitor of CYPs [201]. Therefore, we next optimized DMSO concentration over 
a range of substrate concentrations (Figure 3.1C) and found the largest response 
using a substrate concentration of 8 µM in 0.25% DMSO. Finally, we optimized 
for time to assure linear product formation (Figure 3.1D) and found that product 
formation is linear between 5 and 20 min. We concluded from the optimization 
experiments that incubations with liver bank HLMs be carried out with 5 µg total 
protein and 8 µM final substrate concentration for 10 min. 
 
3.C.ii. Subject Demographics 
Demographics are listed in Table 3.1. Males made up 56.8% and Caucasian was 
the most common ethnicity at 95.4%. Other ethnicities are reported at less than 
3%. At the time of writing this thesis, the only data received on genotypes was for 
64 livers; 48 are wild-type (75%), 14 are heterozygote (21.9%), and 2 are 
homozygote for the *1G SNP (3.1%). Medications were not reported for all 
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samples, however, 12 were reported to be taking a CYP3A4 inducer (3.7%) and 
18 were reported to be taking a CYP3A4 inhibitor (5.6%).  
 
3.C.iii. Analysis of CYP3A4 Activity 
Total CYP3A4 metabolic rate ranged from non-detectable to 10.3 pmol/µg 
protein/min (Figure 3.2) in 324 livers, demonstrating a huge variability in the 
CYP3A4 activity. Pooled HLMs were used as a positive control. The average rate 
is 1.64 ± 0.30 pmol/µg protein/min, making the interday coefficient of variation 
18%.  
 
The CYP3A4 metabolic rates of 64 genotyped livers are stratified by genotype: 
CYP3A4*1/*1 (n=48), CYP3A4*1/*1G (n=14), and CYP3A4*1G/*1G (n=2) (Figure 
3.3). There was no statistical difference between any genotypes (p=0.519), 
however, there was a trend towards increased activity in CYP3A4*1G 
homozygous individuals, although numbers were small.  
 
A linear regression analysis was performed with all data/variables reported from 
the liver bank with the HLMs. All variables, including genotype and gender, did 
not significantly impact the CYP3A4 rate. 
 
3.4. Discussion 
The demographics of the liver samples are not very diverse. The majority of the 
samples are Caucasian (95.4%), male (56.8%), and procured from patients who 
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were between the ages of 40 and 59 (32.4%) (all are independent variables). 
There are few samples that are classified as Black (n=5), Asian (n=1), and 
Hispanic (n=2). Therefore, it is difficult to tease out an effect from ethnicity due to 
limited sample number in this liver bank. Patients on medications that induce or 
inhibit CYP3A4 were also few (n=7 and 5, respectively), again, making it difficult 
to find significance on its effect on CYP3A4 metabolism. Patients classified as 
taking medications that induce CYP3A4 were taking, phenytoin, a strong inducer,  
and patients taking CYP3A4 inhibitors were taking amiodarone and cyclosporine, 
both weak inhibitors, and erythromycin, a moderate inhibitor. No donors were 
taking a strong inhibitor. There were several samples that had no report of 
medications, reporting of medications could have accounted for some 
interindividual variability. Regardless, all variables reported had no significant 
effect on the measured CYP3A4 metabolism rate in human liver microsomes. 
This was a bit unexpected as it is reported that females can express up to 2-fold 
higher levels of CYP3A4 in vivo [136]. Also, there appears to be a trend that liver 
microsomes with higher protein contents tend to have a higher CYP3A4 
metabolism rate, even after normalized to protein content (Figure 3.5). Although, 
again, this is statistically insignificant when analyzed in a multivariable regression.  
 
We next further examined the effect of only the CYP3A4*1G genotype on 
CYP3A4 metabolism. The average rate was determined of each genotype and 
an ANOVA was performed to identify if there was any difference between the 
three average rates. This, too, was not statistically significant (p=0.51898). 
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However, there is a trend toward increasing function of the CYP3A4*1G 
genotype. With only 64 genotyped HLMs, only two were identified as 
CYP3A4*1G/*1G. When the rest of the liver bank is genotyped and included in 
the statistical analysis, there should be more homozygote *1G samples identified, 
resulting in an increase in statistical power. This may help determine if there is 
truly an increase in enzyme activity due to CYP3A4*1G genotype.  
 
Our current data do not allow us to make a definite prediction of CYP3A4*1G 
impact on CYP3A4 metabolism. There was no statistical significance between 
CYP3A4*1G genotype and CYP3A4 expression or activity. However, at the 
writing of this thesis, of the 324 microsomes with activity data, we only have 
genotypes reported for 64 microsomes. When the genotypes of the other 260 
genotypes are incorporated in the analysis, perhaps significance can be teased 
out with the higher sample numbers and higher power. Until then, our data 
suggest that CYP3A4*1G has little significance on total metabolism and does not 
account for measured interindividual variability.  
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Table 3.1. Human Liver Microsome Demographics 
 
 Percentage n 
Gender 
Male 56.8% 184 
Female 42.0% 136 
Unreported 1.2% 4 
Ethnicity 
Caucasian 95.4% 309 
Black 2.8% 9 
Hispanic 0.6% 2 
Asian 0.3% 1 
Unknown 0.9% 3 
Age 
0 – 19 22.2% 72 
20 – 39 17.3% 56 
40 – 59 32.4% 105 
60 – 79 20.1% 65 
80 – 99 1.5% 5 
Unknown 6.5% 21 
Genotype 
CYP3A4*1/*1 14.5% 47 
CYP3A4*1/*1G 4.3% 14 
CYP3A4*1G/*1G 0.6% 2 
Unknown 80.6 261 
CYP3A4 Inducers 
No 39.8% 129 
Yes 3.7% 12 
Unknown 56.5% 183 
CYP3A4 Inhibitors 
No 38.3% 124 
Yes 5.6% 18 
Unknown 56.2% 182 
 
Human liver microsomes demographics reported from human liver bank (University of 
Washington) (n = 324). 
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 C. D. 
	  
Figure 3.1. Optimization of CYP3A4 Activity in Pooled Human Liver Microsomes. A. 
Titration curve of total protein content of pooled. B. Linear range of total protein content 
titration curve. C. DMSO titration. D. Time curve completed to determine linear range of 
product formation. 
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Figure 3.2. CYP3A4 Interindividual Variability Measured in Human Liver 
Microsomes. 5 µg of liver microsome total protein was incubated with 8 µM luciferin IPA 
for 10 minutes. Detection reagent was added and luminescence was quantitated on a 
microplate reader (n=324).  
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Figure 3.3. CYP3A4 Activity in Human Liver Microsomes. HLMs were stratified by 
CYP3A4 genotype (CYP3A4*1/*1 n=48; CYP3A4*1/*1G n=14; CYP3A4*1G/*1G n=2). 
Positive controls were run in duplicate. An ANOVA found no statistical differences 
between genotype (p=0.51898). 
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A.  
  
B. 
	    
  
Figure 3.5. Relationship Between Human Liver Microsome Total Protein Content 
and CYP3A4 Rate. A. Although there is no significant statistical relationship between 
total protein content and CYP3A4 metabolism rate, there is a trend between higher 
protein content and increased CYP3A4 rate. (n=324) B. Data points with rates greater 
than 5 pmol/ug protein/min were removed (n=322) (R=0.43). 
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Chapter IV: Summary and Future Directions 
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The goal of my research project was to decipher the functional consequence of 
the genetic variant CYP3A4*1G. I used in vitro models to assess CYP3A4 mRNA 
and protein expression and activity in lymphocyte cells and human liver 
microsomes.  
 
We hoped to use lymphocyte cell lines, with the genotypes CYP3A4*1/*1, 
CYP3A4*1/*1G, and CYP3A4*1G/*1G, as surrogates of CYP3A4 drug 
metabolism. This convenient, limitless resource with known genotypes would 
have been ideal to study the SNP of interest. Also, the ability to quantitate 
CYP3A4 mRNA, protein, and activity could have huge implications in clinical field 
with the ability to phenotype patients with a single blood draw. Despite using a 
sensitive, luminescent detection method to measure CYP3A4 activity, we were 
unable to observe CYP3A4 activity in the lymphocytes. Therefore, lymphocytes 
do not make good surrogate markers for drug metabolism and cannot be used to 
measure a patients’ CYP3A4 drug metabolism rate and to make any conclusions 
as the functional consequence of the CYP3A4*1G genetic variant.  
 
The second part of my research involved using human liver microsomes to 
assess the functional consequence of CYP3A4*1G variant. CYP3A4 activities 
were measured in 324 human liver microsomes (HLMs). At the time of writing 
this thesis, only 64 of these HLMs have been genotyped: 48 were homozygous 
wild-type CYP3A4*1/*1, 14 heterozygous CYP3A4*1/*1G, and 2 homozygous for 
CYP3A4*1G/*1G. Although a trend was observed towards increased activity in 
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the CYP3A4*1G containing livers, a multivariable regression and ANOVA both 
found no significance of the CYP3A4*1G genetic variant. Until the genotypes of 
the remaining HLMs are known, there is not enough power to determine the 
effect of CYP3A4*1G. 
 
In addition to incorporating the genotype of the remaining livers into the analysis, 
we will also normalize to the CYP3A4 protein levels, quantified by mass 
spectrometry, both completed at the University of Washington, as soon as the 
data collection is completed. However, in future work, I would measure the 
protein content of known CYP3A4 transcription factors, pregnane X receptor, 
constitutive androstane receptor, retinoid receptor, and hepatocyte nuclear factor 
in the human liver microsome samples [202, 203]. This would allow us to account 
for any of the CYP3A4 interindividual variability due to increased or decreased 
expression of transcription factors and may help us better ascertain any changes 
in function due to genetic variations in CYP3A4. 
 
Other studies have found that CYP3A4*1G either causes increased [137, 138, 
140] or decreased [116, 118-120] clearance in vivo. These mixed results could 
arise from the contribution of other CYP3A proteins. CYP3A7 may have minor 
impact as it is only expressed in 10% of adults, however, it can have large impact 
in CYP3A drug metabolism in those individuals as CYP3A7 has been reported to 
contribute up to 40% of CYP3A content [145-147]. CYP3A5 genotype could play 
a larger role in interindividual variability in CYP3A drug metabolism. In those who 
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express CYP3A5, CYP3A5 makes up 50% of CYP3A content [100]. Because of 
the linkage disequilibrium found between CYP3A4*1G and CYP3A5*1 found in 
HapMap populations, it is difficult to identify the functional consequence of 
CYP3A4*1G. However, a novel break in the linkage of CYP3A4*1G and 
CYP3A5*3 has been uncovered in the Confederated Salish and Kootenai Tribes. 
Due to the high CYP3A5*3 allele frequency in this population, many would carry 
both the CYP3A4*1G allele and the CYP3A5*3 allele. Studying this population, 
would allow us to assay for changes in CYP3A4 drug metabolism without the 
contribution from CYP3A5. Therefore, our laboratory has a proposed study to 
evaluate the CYP3A4*1G genetic variant in the CSKT population using an oral, 
subtherapeutic dose of midazolam, a CYP3A4 probe drug. Blood and urine will 
be collected to measure midazolam and its metabolite over time. This study will 
shed light on the CYP3A4*1G functional consequence unlike any other study has 
been able to do; we will be able to unequivocally assay for CYP3A4*1G 
metabolism. 
 
In conclusion, changes in the CYP3A4 metabolism rate due to the *1G SNP can 
have wide implications, especially in Japanese, Chinese, and CSKT populations, 
where the *1G allele has been reported in high frequencies [90]. Because 
CYP3A4 is responsible for metabolizing up to 50% of medications currently on 
the market [129, 142-144], any changes in its metabolism rate will affect the 
clearance of several medications. Also, any changes in CYP3A4 metabolism 
rates can be exaggerated when inherited with nonfunctional CYP3A5, like that 
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seen in the CSKT population. It is important to identify the effect of the 
CYP3A4*1G genetic variant to better predict pharmacokinetic and 
pharmacodynamic changes to lead to increased drug efficacy and decreased 
toxicity.  
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